Effects of antihypertensive therapy on progression of diabetic nephropathy  by Luño, José et al.
Effects of antihypertensive therapy on progression of diabetic
nephropathy
JOSE´ LUN˜O, SOLEDAD GARCIA DE VINUESA, FRANCISCO GOMEZ-CAMPDERA, INMACULADA LORENZO, and
FERNANDO VALDERRA´BANO
Servicio de Nefrologia, Hospital General Universitario Gregorio Maran˜on, Madrid, Spain
Effects of antihypertensive therapy on progression of diabetic
nephropathy. There is a clear relationship between hypertension
and the microvascular complications of diabetes. Genetic predis-
position to hypertension has been correlated to the risk of diabetic
nephropathy in type I diabetes, and hypertension is a well known
risk factor for developing nephropathy in patients with type II
diabetes. Multiple studies have emphasized the importance of
hypertension on renal disease progression, and blood pressure
control with conventional antihypertensive drugs slows the rate of
renal function loss in diabetic nephropathy. Furthermore, evi-
dence of the role of renin-angiotensin system (RAS) on progres-
sion of renal damage has focused much interest on the therapeutic
action of the RAS blockade. In patients with type I diabetes,
blocking the RAS with angiotensin converting enzyme (ACE)
inhibitors prevents progression from microalbuminuria to overt
nephropathy, and in overt nephropathy decreases the gradual loss
of renal function beyond its blood pressure lowering effect. Less
clinical information is available in type II diabetic nephropathy,
but our experience and some recent studies suggest that ACE
inhibitors also have a renoprotective action in type II diabetes.
The role of calcium channel blockers in diabetic nephropathy is
not clear. Several short-term studies with the first generation
dihydropyridine calcium antagonists showed a lower effect on
urinary albumin excretion and a more rapid progression to renal
failure than with ACE inhibitors. However, other calcium channel
blockers, particularly of the non-dihydropyridine type, have been
shown to have a beneficial effect on diabetic nephropathy, de-
creasing proteinuria and slowing progression.
Diabetic nephropathy is currently the most important
cause of end-stage renal disease in Western countries,
mainly due to a gradual increase in the incidence of renal
failure in patients with type II, non-insulin dependent
diabetes mellitus (NIDDM) in recent years, particularly in
the USA [1], but also somewhat later in European coun-
tries [2]. These data correct the previous erroneous esti-
mate of the incidence of diabetic nephropathy in type II
diabetes in the early eighties [3]. In fact, diabetic nephopa-
thy can occur to the same extent with type I and type II
diabetes, and almost 50% of patients with both types are at
risk of developing overt nephropathy 25 years after the
onset of the disease [4].
Diabetic nephropathy is a clinical syndrome character-
ized by the presence of persistent albuminuria (.300 mg/24
hr or 200 mg/min) associated with blood pressure elevation
and a gradual decline in glomerular filtration rate. Some
studies have shown that early increased excretion of urinary
albumin, as measured by sensitive methods able to detect
albuminuria below the levels from 15 to 200 (mg/min
detected in conventional tests, the so-called microalbumin-
uria, clearly predicts progression to diabetic nephropathy in
type I insulin-dependent diabetes mellitus (IDDM) [5] and
less clearly in NIDDM patients [6].
The pathogenesis of diabetic nephropathy is not com-
pletely understood. Brenner and coworkers postulated a
causal relationship between glomerular hypertension oc-
curring in the earliest phase of the disease and glomerular
damage in diabetic nephropathy [7, 8], and this “hemody-
namic theory” has been confirmed by multiple experimen-
tal studies [9–13]. These hemodynamic changes and other
non-hemodynamic factors related to chronic hyperglyce-
mia, including sorbitol deposition, formation of glycosyla-
tion end-products with glomerular proteins and a number
of vasoactive hormones, growth factors and cytokines, are
important determinants in the development of diabetic
nephropathy [14–17]. However, normalization of glomeru-
lar hypertension and control of systemic blood pressure
appear to be essential to slow the progression of renal
disease [18]. Several clinical studies have shown that blood
pressure lowering with different types of antihypertensive
drugs reduces the rate of decline of renal function in
diabetic nephropathy [19–21], and more recent evidence in
animal models and some controlled, prospective clinical
trials, particularly in IDDM patients, suggests that there is
an added renoprotective effect beyond its action on blood
pressure when antihypertensive therapy with angiotensin
converting enzyme (ACE) inhibitors or angiotensin II
receptor antagonists are used [22–29]. However, clinical
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evidence of the beneficial effect of renin-angiotensin sys-
tem (RAS) blockade in the progression of diabetic ne-
phropathy is less convincing in type II diabetics [2].
GENETIC PREDISPOSITION TO HYPERTENSION
AND DIABETIC NEPHROPATHY
There is some evidence that genetic predisposition to
hypertension increases susceptibility to diabetic nephropa-
thy [30]. In patients with type I diabetes, some authors have
found that having a parent with hypertension increases the
risk of nephropathy by almost four times compared to
patients with no hypertensive parents [31]. Familial clus-
tering of hypertension and cardiovascular complications is
also well recognized in patients with type I [32] or type II
diabetes with nephropathy [2], and a history of cardiovas-
cular disease in parents also increases the risk of develop-
ing nephropathy.
Abnormalities of the Na1/H1 exchanger, a marker of
genetic predisposition to hypertension, have also been
related to the risk of nephropathy, and some studies have
demostrated an increased activity of the Na1/Li1 counter-
transport in red blood cells in patients with type I diabetes
and nephropathy, as well as in their parents, compared to
controls [31, 33]. This excess risk of renal disease associated
with increased activity of the Na1/Li1 countertransport in
type I diabetic patients was mainly evident in patients with
poor glycemic control during the first decade of diabetes
[31]. However, this altered Na1/Li1 countertransport ac-
tivity in red blood cells of type I diabetic patients with
nephropathy has not been found in all studies [34, 35].
Genes of the RAS have also been involved in the risk of
nephropathy in IDDM. Nevertherless, this relationship of
the insertion/deletion (I/D) polymorphism in the ACE gene
to diabetic nephropathy [36] was not confirmed by all
authors [37]. However, recent data suggest that type I
diabetic patients who are homozygous for the D allele
progress more rapidly to renal failure [38].
HYPERTENSION AS A RISK FACTOR IN DIABETIC
NEPHROPATHY
High blood pressure is a common and early finding in
diabetic nephropathy. In type I diabetes, blood pressure
tends to increase slightly, concomitant with the onset of
persistent microalbuminuria [39]. These changes in blood
pressure may be detected even before transition to mi-
croalbuminuria occurs if ambulatory blood pressure moni-
toring is used. In normoalbuminuric IDDM patients,
Poulsen et al found a clear positive relationship between
ambulatory blood pressure and urinary albumin excretion
as measured by RIA [40]. Attenuated circadian rhythm
with reduced normal night drop in blood pressure has also
been reported in diabetic patients. Using ambulatory blood
pressure measurements, the prevalences of non-dippers
(average reduction in systolic and diastolic blood pressure
from day to night ,10%) among type I diabetics with
normoalbuminuria, microalbuminuria and overt nephrop-
athy are 19%, 39% and 46%, compared to 10% of non-
dippers among non-diabetic subjects [41]. The prevalences
of non-dippers among elderly type II diabetics with nor-
moalbuminuria, microalbuminuria and overt nephropathy
increase to 42%, 50% and 58% respectively, as compared
to only 14% of non-dippers in the non-diabetic control
population [42].
In type II diabetes, hypertension, as a facet of the
metabolic syndrome, is usually present for years before the
appearance of nephropathy or even before the onset of
diabetes. Hypertension is a frequent finding in type II
diabetes, and its prevalence ranges from 50% to 70% of all
patients with type II diabetes without proteinuria, increas-
ing to 80% when proteinuria appears and to almost 100%
in patients with type II diabetes and renal failure [2].
The presence of high blood pressure before the onset of
diabetes is significant risk factor for the development of
nephropathy in NIDDM [43]. However, in both types of
diabetes hypertension enhances progression from mi-
croalbuminuria to overt nephropathy [44–45] and acceler-
ates the rate of decline in renal function, thus increasing
the prevalence and severity of hypertension in a vicious
cycle leading to more advanced nephropathy [46–48].
Several studies have shown that hypertension is a strong
progression factor for renal failure in diabetic nephropathy.
Comparing the progression of renal failure in both types of
diabetes, Biesenbach, Janko and Zazgomik found a more
rapid progression in both type I and type II diabetics when
systolic blood pressure was higher than 160 mm of Hg [46],
and since the first observations of Danish authors showing
that blood pressure control attenuates the gradual loss of
renal function in diabetic nephropathy [19, 20], many
others and some long-term studies have confirmed that in
diabetic patients with proteinuria, lowering of systemic
blood pressure with conventional antihypertensive drugs
slows the rate of decline in renal function [49, 50].
ROLE OF THE RENIN-ANGIOTENSIN SYSTEM IN
PROGRESSION OF DIABETIC NEPHROPATHY
Experimental studies in animals with diabetic kidney
disease have shown that blockade of the RAS with ACE
inhibitors or angiotensin II receptor antagonists preserves
renal function [22–24], suggesting an essential role for
intrarenal angiotensin II in the progression of renal dam-
age in diabetic nephropathy. The importance of the RAS in
the pathogenesis of diabetic nephropathy is suggested by
multiple experimental and clinical studies [25]. Angiotensin
II is a powerful vasoconstricting agent that acts not only by
regulating systemic hemodynamics. Locally generated in-
traglomerular angiotensin II may cause constriction of
mesangial cells and afferent–and particularly efferent–
arterioles, resulting in glomerular hypertension. In addition
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to this glomerular hemodynamic action, angiotensin II also
acts as a growth factor for renal cells, inducing the expres-
sion and renal synthesis of other autocrine factors and
cytokines, including transforming growth factor beta (TGF-
B1) [51], which in turn stimulates mesangial and epithelial
cells and fibroblasts to produce extracellular matrix pro-
teins and promotes fibrosis, thus contributing to progres-
sive renal damage [25]. Angiotensin II also causes changes
in the filtration properties of the glomerular basement
membrane, increasing its permeability and aggravating
proteinuria [53].
The significant role attributed to glomerular hyperten-
sion in the pathogenesis of diabetic nephropathy [8] sug-
gested that RAS inhibition could be particularly useful in
this condition. Apart from the beneficial antihypertensive
effect, RAS blockade normalized glomerular capillary pres-
sure as a result of the attenuation of the angiotensin II
vasoconstrictive effect on glomerular efferent arterioles
and inhibited all other non-hemodynamic angiotensin-
mediated effects, resulting in a decrease in proteinuria and
slowing progression [28].
Since the first report of Taguma, Kitamoto and Futaki
showing a beneficial effect of captopril on proteinuria in
nephrotic uremic diabetic patients [54], many other studies
have documented the renoprotective benefits of ACE
inhibitors to decrease urinary albumin excretion and to
prevent the loss of renal function in IDDM patients with
early and overt nephropathy, regardless of changes in blood
pressure [28, 52]. However, evidence for the beneficial
effect of ACE inhibition in type II diabetic nephropathy is
not so convincing, owing to the absence of long-term,
controlled crinical trials [2].
ANTIHYPERTENSIVE DRUG THERAPY PREVENTS
PROGRESSION FROM MICROALBUMINURIA TO
OVERT DIABETIC NEPHROPATHY
Based on this putative renoprotective effect of ACE
inhibitors with no detectable changes in blood pressure,
several investigators have examined the effect of ACE
inhibitor therapy in normotensive IDDM patients with
microalbuminuria. Viberti et al, on behalf of the European
Multicenter Trial, clearly established that progression to
clinical proteinuria is significantly less when normotensive
IDDM patients are treated with captopril compared to a
placebo [27]. The observation that ACE inhibitor therapy
delays the development of diabetic nephropathy in normo-
tensive IDDM with persistent microalbuminuria has been
confirmed in several studies [52, 55, 57], and also in both
IDDM and NIDDM diabetic patients with early nephrop-
athy and hypertension [58–61]. In patients with early
diabetic nephropathy, treatment with ACE inhibitors tends
to slightly decrease glomerular filtration rate and filtration
fraction, particularly in hyperfiltering patients [52].
As opposed to ACE inhibitors, the use of calcium
channel blockers in early diabetic nephropathy is less well
defined. Calcium antagonists inhibit the vasoconstrictive
effect of angiotensin II through the blockade of calcium-
dependent mechanisms, but their ability to reduce urinary
albumin excretion and to preserve renal function has been
questioned due to the vasodilation effect on afferent arte-
rioles, which impedes reduction of intraglomerular pres-
sure in spite of systemic blood pressure control [62].
Furthermore, experimental studies have shown that dihydro-
pyridine calcium channel blockers, such as nifedipine, do
not prevent the development of glomerulosclerosis due to
their inhibitory action on renal self-regulation [63–65].
However, these drugs may also have other beneficial effects
on renal damage mediated by mechanisms unrelated to
their blood pressure lowering effects. Calcium channel
blockers have been shown to reduce mesangial uptake of
macromolecules induced by angiotensin II [66], and to
inhibit mesangial cell proliferation [67].
The effect of nifedipine on microalbuminuric, normoten-
sive type I (IDDM) diabetes was studied by Schnack et al in
a randomized, double-blind trial, showing that treatment
with nifedipine for a year significantly decreases urinary
albumin excretion and glomerular filtration rate compared
to placebo [68]. In both type I and type II patients, The
Melbourne Diabetic Nephropathy Study compared nifedi-
pine and perindopril in normotensive and hypertensive
diabetic patients with microalbuminuria, and showed that a
12-month treatment with both drugs significantly decreased
blood pressure and albuminuria in hypertensive microalbu-
minuric patients, while in normotensive patients there was
no significant reduction in albuminuria with either regimen
[58].
Agardh et al compared nifedipine with the ACE inhibi-
tor lisinopril in a double-blind, randomized, parallel and
multicenter 12-month trial with 335 hypertensive type II
diabetic patients with early nephropathy [59]. These au-
thors clearly demostrated that treatment with lisinopril has
a significantly greater beneficial effect on albuminuria than
nifedipine, despite similar effects on ambulatory blood
pressure. In this study there was no change in the glomer-
ular filtration rate during either treatment [59]. However,
several authors using another dihydropyridine calcium
channel blocker, nitrendipine, in type I and type II diabetic
hypertensive patients with early diabetic nephropathy have
found a 17% to 44% increase in glomerular filtration rate
associated with a significant decrease in albuminuria [60,
61, 69, 70].
ANTIHYPERTENSIVE TREATMENT IN OVERT
DIABETIC NEPHROPATHY
There is large body of evidence in the literature demon-
strating that blood pressure lowering decreases proteinuria
and reduces the rate of decline of renal function in diabetic
nephropathy secondary to type I diabetes, particularly
when ACE inhibitors are used [20, 28, 49, 71].
The most complete clinical trial of the effects of ACE
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inhibitors on overt diabetic nephropathy was reported by
Lewis et al on behalf of the Collaborative Study Group in
1993 [28]. In this study, 409 patients with insulin-dependent
diabetes, clinical proteinuria (.500 mg/dl) and serum
creatinine ,2.5 mg/dl were randomized to receive captopril
or placebo during a median follow-up of 2.7 years. ACE
inhibition treatment in this study led to decreased protein-
uria and to a 50% reduction in the risk for doubling serum
creatinine, dialysis and death. The risk reduction associated
with captopril treatment was not significantly different in
hypertensive compared to normotensive patients, and after
adjusting for blood pressure during the treatment period,
the lesser progression found in the captopril group was
independent of the effect on systemic blood pressure [28].
Evidence for this beneficial effect of ACE inhibitors on
progression is less compelling in type II diabetic nephrop-
athy. Bakris et al compared the effects of the ACE inhibitor
lisinopril with a non-dihydropyridine calcium channel
blocker, diltiazem or verapamil, and atenolol during a
six-year follow-up study on 52 NIDDM patients with dia-
betic nephropathy and hypertension, and found that uri-
nary protein excretion was reduced with lisinopril and
verapamil or diltiazem, but not with atenolol, despite
similar levels of blood pressure control. The mean rate of
decline of creatinine clearance was 20.98 6 0.44 in the
lisinopril group, 21.44 6 0.63 in the non-dihydropyridine
calcium antagonists group, and 23.48 6 1.1 ml/min/year/
1.73 m2 in the atenolol group [72].
We have studied 91 NIDDM patients with diabetic
clinical nephropathy. They all had clinical proteinuria .500
mg/dl and moderate renal failure (CCr 25–70 ml/min).
Fifty-seven of them were treated with ACE inhibitors and
the other 34 patients with dihydropyridine calcium channel
blockers during a follow-up period of two years. Target
blood pressure levels were a systolic blood pressure below
140 mm Hg and a diastolic blood pressure below 90 mm
Hg. Other drugs different from calcium antagonists or
ACE inhibitors, respectively, were added when required to
control hypertension in each group of patients. No previous
differences were found in each group with regards to age,
creatinine clearance or proteinuria, but systolic and dia-
stolic blood pressures were higher in the ACE inhibitor
group, since a drug of this class was given to patients with
uncontrolled blood pressure before the start of the study,
and only those patients with controlled blood pressure
on calcium antagonists were maintained in this group
(Table 1).
The primary end point of this study was the need for
dialysis/transplantation or death. The average follow up
was 22 6 6 months, and 14 patients reached the primary
end point; 11 patients showed end-stage renal disease (4 in
the ACE inhibitor group and 7 in the calcium antagonist
group) and 3 patients died during the study. One died from
cardiovascular disease in the ACE inhibitor group and two
patients died in the calcium antagonist group (one cardio-
vascular death and one infectious death). The rate of
decline in creatinine clearance was 0.6 ml/min/month in the
ACE inhibitor group, compared to 0.95 ml/min/month in
the calcium channel blocker group. The median urinary
protein excretion decreased 225% in the ACE inhibitor
group, compared to a 49% increase in patients on calcium
antagonists (Table 2).
Conversely, the effect of calcium channel blockers on
renal function in overt diabetic nephropathy is not clearly
determined. Some studies have shown that non-dihydropy-
ridine calcium antagonists (diltiazem and verapamil) ap-
pear to have similar efficacy in controlling blood pressure,
reducing proteinuria and slowing the rate of decline in
renal function [72–74]. However, most studies conducted
with the first generation dihydropyridine calcium channel
blocker nifedipine show an increased progression of renal
failure in spite of blood pressure control [75–77].
In a meta-regression analysis of 100 studies, Kasiske et al
found that only ACE inhibitors were able to reduce the
level of proteinuria and slow the rate of decline in renal
function regardless of changes in blood pressure [29], and
Weidmann et al, in a recent meta-analysis of the effects of
different antihypertensive drugs on renal function in type I
and type II diabetic patients with clinical nephropathy,
showed a significantly lower progression with ACE inhibi-
tor therapy than with conventional antihypertensive drugs
(diuretics and/or beta blockers) or nifedipine. In this
meta-analysis, some conflicting data emerged in analyzing
the effects of different calcium antagonists. In five studies
including only 63 patients with a median follow-up of 16.9
months, treatment with calcium antagonists other than
nifedipine was associated to a 42% decrease in proteinuria
and to a 2% increase in GFR per year. However, the
number of cases treated with calcium antagonists other
than nifidepine was too small to allow a clear interpretation
of this possibly beneficial effect (Table 3) [77].
As suggested above, there is clear evidence that treat-
ment with ACE inhibitors slows the progression of diabetic
nephropathy beyond their effect on blood pressure, and
Table 1. Type II diabetes and clinical nephropathy
ACE inhibitors Calcium antagonists
Age 66.7 6 8.1 68.4 6 9.2
Creatinine clearance ml/min 44.2 6 12 43.4 6 17
Proteinuria g/day 3.9 6 3.1 4.1 6 3.3
HDL mg/dl 46 6 11 43 6 12
LDL mg/dl 170 6 46a 147 6 35
SBP mm Hg 160 6 24a 149 6 18
DBP mm Hg 84 6 11a 79 6 11
Comparative data before the start of the study, between patients on
ACE inhibitors and those on dihydropyridine calcium antagonists.
Mean 6 SD. Abbreviations are: HDL, high density lipoprotein; LDL, low
density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood
pressure.
a P , 0.05
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recent published data also show that non-dydropyridine
calcium channel blockers decrease proteinuria and have a
beneficial effect on renal function compared to conven-
tional antihypertensive drugs when used in type II diabetic
patients with nephropathy [72]. Many hypertensive patients
with diabetic nephropathy require more than one drug to
control their blood pressure, and this further promotes the
combination of ACE inhibitors and calcium channel block-
ers to achieve an effective therapy when treating hyperten-
sive diabetic patients with nephropathy. This concept of
combined therapy appears attractive to some authors, since
the two different classes of antihypertensive drugs may
provide greater additive effects on proteinuria and nephro-
protection than would be expected for each drug alone [76].
Carmines and Navar, using a model of isolated, perfused
juxtamedullary nephrons pretreated with captopril, found
that the addition of both verapamil and diltiazem enhanced
efferent arteriolar dilation [78]. Other studies in animal
models have shown that the combination of an ACE
inhibitor and a calcium antagonist had additional beneficial
effects on proteinuria and glomerulosclerosis [79, 80].
These experimental data have stimulated several authors to
investigate the effect of combination therapy (most studies
have been done with an ACE inhibitor plus a non-dihydro-
pyridine calcium channel blocker) in patients with diabetic
nephropathy, and preliminary data from short-term studies
suggest that this combination has an antiproteinuric effect,
at comparable blood pressure levels, greater than that seen
with either drug alone [81–83]. However, it is still unknown
whether the association therapy combining ACE inhibitors
and calcium antagonists will have any benefits in slowing
the progression of diabetic nephropathy [84].
CONCLUSIONS
Hypertension is a risk factor for developing diabetic
nephropathy, and also a strong progression factor for renal
failure contributing to other diabetic complications, includ-
ing heart and vascular atherosclerotic disease. Since high
blood pressure clearly worsens the prognosis in diabetic
patients with nephropathy, this strong risk factor must be
strictly controlled. Some recent studies have demostrated
that progression from microalbuminuria to clinical protein-
uria could be delayed if microalbuminuric type I diabetic
patients are treated with ACE inhibitors. This evidence
promotes prevention programs for the detection of mi-
croalbuminuria from the earliest phase of diabetes, partic-
ularly in patients with type I diabetes. Diabetic patients at
risk should participate in intervention programs for blood
pressure control, and if microalbuminuria occurs, adminis-
tration of an ACE inhibitor even in the presence of normal
systemic blood pressure values may prevent progression
from microalbuminuria to overt nephropathy. Further-
more, there is strong evidence indicating that in type I
diabetic patients with overt nephropathy, antihypertensive
treatment with ACE inhibitors decreases proteinuria and
slows progression to renal failure beyond their effect on
blood pressure. Although in type II diabetes the clinical
evidence of the advantage of ACE inhibitors over other
antihypertensive drugs with regards to the progression of
nephropathy is not as convincing, some recent studies and
Table 2. Effects of angiotensin converting enzyme (ACE) inhibitors and dihydropyridine calcium antagonists in patients with type II (NIDDM)
and clinical nephropathy
ACE inhibitors Calcium antagonists
Basal/one year/end % change Basal/one year/end % Change
GFR ml/min 44 6 12/37 6 12/31 6 8 230%a 43 6 17/29 6 12/22 6 11 253%
Proteinuria g/day 3.9 6 3.1/3.2 6 3/2.9 6 3 225%a 4.1 6 3.3/5.3 6 4.7/6.0 6 4.9 146%
LDL mg/dl 170 6 46/160 6 45/157 6 50 28% 147 6 35/143 6 29/145 6 29 11%
SBP mm Hg 160 6 24/152 6 18/149 6 15 27% 149 6 18/147 6 12/145 6 13 23%
DBP mm Hg 84 6 11/81 6 8/79 6 10 26% 79 6 11/78 6 9/77 6 9 23%
Data are mean 6 SD. Data were obtained from 91 patients with type II diabetic clinical nephropathy; 57 have been treated with ACE inhibitors and
34 with dihydropyridine calcium channel blockers. Follow-up was 22 6 6 months. Basal, One year of follow-up and End of the study.
Abbreviations are: GFR, glomerular filtration rate; LDL, low density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.
a P , 0.05 comparing % changes between Basal and End periods of the ACE inhibitors vs. calcium antagonist groups.
Table 3. Effects of different antihypertensive drugs on renal function in diabetic clinical nephropathy
Treatment (N)
Follow-up
months
% Change in
proteinuria
% Change in GFR
%/month % Change in MBP
Placebo (244) 21.2 (10.5–31.9) 39 (27/85) 20.7 (21.3/0.0) 22 (29/5)
Diuretics and/or Beta-blockers (213) 16.5 (8.3–24.7) 220 (230/210) 20.8 (21.6/0.1) 210 (212/28)
ACE inhibitors (489) 9.5 (5.0–14.1) 253 (293/214) 20.1 (21.3/1.1) 216 (231/22)
Ca antagonists except nifedipine (63) 16.9 (1.9–35.7) 242 (264/220) 0.2 (20.6/0.9) 216 (223/210)
Nifedipine (75) 8.0 (3.1–12.8) 22 (221/16) 24.0 (27.4/20.7) 212 (216/28)
From the meta-analysis of Weidmann et al [77]. Reprinted with permission from Nephrology Dialysis and Transplantation.
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our own experience suggest that antihypertensive treat-
ment with ACE inhibitors in NIDDM patients also has
more favorable effects on renal disease progression. Fac-
tors different from an effective blood pressure control that
must be considered when treating diabetic patients with
hypertension are the lack of adverse effects on metabolic
control. ACE inhibitors, probably angiotensin II receptor
antagonists and certain calcium channel blockers, particu-
larly the non-dihydropyridine type, do not have a negative
effect on glucose and lipid metabolism added to their
renoprotective effect. This suggests that ACE inhibitors
and non-dihydropiridine calcium channel blockers can be
used as first-line antihypertensive drugs in diabetic patients
with nephropathy. It is unknown whether a combination
therapy of both types of drugs offers any advantages in
slowing the rate of decline in renal function. The beneficial
effect of angiotensin II receptor antagonists on progression
of renal failure in diabetic nephropathy needs to be con-
firmed in long-term clinical studies.
Reprint requests to Jose´ Lun˜o, Servicio de Nefrologia, Hospital General
Universitario Gregorio Maran˜on, Dr Esquerdo 46, Madrid 28007, Spain.
E-mail: jluno@farmanet.com
REFERENCES
1. US RENAL DATA SYSTEM: USRDS 1994 Annual Data Report. Inci-
dence and Causes of Treated Renal Disease. Am J Kidney Dis
24(Suppl 2):S48–S56, 1994
2. RITZ E, STEFANSKI A: Diabetic Nephropathy in type II diabetes. Am J
Kidney Dis 27, 2:167–194, 1996
3. FABRE J, BALANT LP, DAYER PG, FOX HM, VERNET AT: The kidney
in maturity onset diabetes mellitus: A clinical study of 510 patients.
Kidney Int 21:730–738, 1982
4. HASSLACHER C, RITZ E, WAHL P, MICHAEL C: Similar risks of
nephropathy in patients with type I or type II diabetes mellitus.
Nephrol Dial Transplant 4:859–863, 1989
5. MOGENSEN CE, CHRISTENSEN CK: Predicting diabetic nephropathy in
insulin-dependent patients. N Engl Med 311:89–93, 1984
6. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and
early mortality in maturity onset diabetes. N Engl J Med 310:356–360,
1984
7. BRENNER BM: Hemodynamically mediated glomerular injury and the
progressive nature of kidney disease. Kidney Int 23:647–655, 1983
8. HOSTETTER TH, TROY JL, BRENNER BM: Glomerular hemodynamics
in experimental diabetes mellitus. Kidney Int 19:410–415, 1981
9. ANDERSON S, MEYER TW, RENNKE HG, BRENNER BM: Control of
glomerular hypertension limits glomerular injury in rats with reduced
renal mass. J Clin Invest 76:612–619, 1985
10. ZATZ R: Haemodynamically mediated glomerular injury: The end of
a 15-year-old controversy? Curr Opin Nephrol Hypertens 5:468–475,
1996
11. CHRISTIANSEN JS, GAMMELGAARD J, FRANDSEN M, PARVING HH:
Increased kidney size, glomerular filtration rate and renal plasma flow
in short term insulin dependent diabetics. Diabetologia 20:451–456,
1981
12. RISER BL, CORTES P, ZHAO X, BERSTEIN J, DUMLER F, NARINS RG:
Intraglomerular pressure and mesangial stretching stimulate extrace-
lular matrix formation in the rat. J Clin Invest 90:1932–1943, 1992
13. SHANKLAND SJ, LY H, THAI K, SCHOLEY JW: Increased glomerular
capillary pressure alters glomerular cytokine expresion. Circ Res
75:844–853, 1994
14. PARVING HH, OSTERBY R, ANDERSON PW, HSUEH WA: Diabetic
nephropathy, in The Kidney, edited by BRENNER BM, Philadelphia,
WB Saunders Company, 1996, pp 1864–1891
15. HOSTETTER TH: Mechanisms of diabetic nephropathy. Am J Kidney
Dis 23:188–192, 1994
16. ADLER S, NAST C, ARTISHEWSKY A: Diabetic nephropathy: Pathogen-
esis and treatment. Ann Rev Med 44:303–315, 1993
17. MYERS BD: Pathophysiology of proteinuria in diabetic glomerular
disease. J Hypertens 8(Suppl 1):S41–S50, 1990
18. BENNETT PH, HAFFNER S, KASISKE BL, KEANE WF, MOGENSEN CE,
PARVING HH, STEFFES MW, STRIKER GE: Screening and management
of microalbuminuria in patients with diabetes mellitus: Recommen-
dations to the Scientific Advisory Board of the National Kidney
Foundation from an ad hoc committee of the Council on Diabetes
Mellitus of the National Kidney Foundation. Am J Kidney Dis
25:107–112, 1995
19. MOGENSEN CE: Long term antihypertensive treatment inhibiting
progression of diabetic nephropathy. Br Med J 285:685–688, 1982
20. PARVING HH, ANDERSEN AR, SMIDT UM, SVENDSEN PA: Early
aggressive antihypertensive treatment reduces rate of decline in
kidney function in diabetic nephropathy. Lancet 1:1175–1179, 1983
21. BREYER JA: Diabetic nephropathy in insulin dependent patients. Am J
Kidney Dis 20:533–547, 1992
22. ANDERSON S, RENNKE HG, GARCIA DL, BRENNER BM: Short and
long term effects of antihypertensive therapy in the diabetic rat.
Kidney Int 36:526–536, 1989
23. YOSHIDA K, YASUJIMA M, KOHZUKI M, KANAZAWA M, ABE K: The
Effects of chronic treatment of calcium channel blockers and angio-
tensin converting enzyme inhibitors on renal function in streptozoto-
cin diabetics rats. Hypertens Res 17:35–41, 1994
24. KOHZUKI M, YASUJIMA M, KANAZAWA M, YOSHIDA K, PING FL,
OBARA K, SAITO T, ABE K: Antihypertensive and renal protective
effects of losartan in streptozotocin diabetics rats. J Hypertens 13:97–
103, 1995
25. EGIDO J: Vasoactive hormones and renal sclerosis. Kidney Int 49:578–
596, 1996
26. FUJIHARA CK, PADILHA RM, ZATZ R: Glomerular abnormalities in
long term experimental diabetes: Role of hemodyamic and nonhemo-
dynamics factors and effects of antihypertensive therapy. Diabetes
41:286–293, 1992
27. VIBERTI G, MOGENSEN CE, GROOP LC, PAULS JF, THE EUROPEAN
MICROALBUMINURIA STUDY GROUP: Effect of captopril on progres-
sion to clinical proteinuria in patients with insulin dependent diabetes
mellitus and microalbuminuria. JAMA 271:275–279, 1994
28. LEWIS EJ, JUNSINKER LG, BAIN RP, ROHDE RD, THE COLLABORATIVE
STUDY GROUP: The effect of angiotensin converting enzyme inhibition
on diabetic nephropathy. N Engl J Med 329:1456–1462, 1993
29. KASISKE BL, ROBERTO SN, MA JZ, KIAO M, KEANE WF: Effect of
antihypertensive therapy on the kidney in patients with diabetes. A
meta-regression analysis. Ann Intern Med 118:129–138, 1993
30. VIBERTI GC, KEEN H, WISEMAN MJ: Raised arterial pressure in
parents of proteinuric insulin-dependent diabetics. Br Med J 95:515–
517, 1987
31. KROLEWSKI AS, CANESSA M, WARRAM JH, LAFFEL LMB, CHRISTLIEB
AR, KNOWLER WC, RAND LI: Predisposition to hypertension and
susceptibility to renal disease in insulin-dependent diabetes mellitus.
N Engl J Med 318:140–145, 1988
32. EARLE K, WALKER J, HILL C, VIBERTI GC: Familial clustering of
cardiovascular disease in patients with insulin-dependent diabetes and
nephropathy. N Engl J Med 326:673–677, 1992
33. WALKER JD, TARIQ T, VIBERTI GC: Sodium-lithium countertransport
activity in red cells of patients with insulin dependent diabetes and
nephropathy and their parents. Br Med J 301:635–638, 1987
34. JENSEN JS, MATHIESEN ER, NORGAARD K, HOMMEL E, BORCH-
JOHNSEN K, FUNDER J, PARVING HH, DECKERT T: Increased blood
pressure and erithrocyte sodium-lithium countertransport activity are
not inherited in diabetic nephropathy. Diabetologia 33:619–624, 1990
35. ELVING LD, WETZELS JFM, DENOBEL E, BERDEN JHM: Erithrocyte
sodium-lithium countertransport is not different in T 1(insulin-depen-
dent) diabetic patients with and without diabetic nephropathy. Dia-
betologia 34:126–128, 1991
36. MARRE M, BERNADET P, GALLOIS Y, SAVAGNER F, GUYENE TT,
HALLAB M, CAMBIEN F, PASSA P, ALHENC-GELAS F: Relationship
Lun˜o et al: Antihypertensive therapy in diabetic nephropathy S-117
between angiotensin I converting enzyme gene polymorphism, plasma
levels,and diabetic retinal and renal complications. Diabetes 43:384–
388, 1994
37. SCHMIDT S, SCHO¨NE N, RITZ E, DIABETIC NEPHROPATHY STUDY
GROUP: Association of ACE genes polymorphism and diabetic ne-
phropathy? Kidney Int 47:1176–1181, 1995
38. JACOBSEN P, TARNOW L, ROSSING P, CAMBIEN F, LECERF L, POIRIER
O, PARVING HH: The insertion/deletion (I/D) polymorphism in the
angiotensin converting enzyme (ACE) gene predicts the progression
of diabetic nephropathy during ACE inhibition (ACEI) in insulin
dependent diabetic (IDDM) patients. (abstract) J Am Soc Nephrol
6:450, 1995
39. MATHIESEN ER, RONN B, JENSEN T, STORM B, DECKERT T: Relation-
ship between blood pressure and urinary albumin excretion in devel-
opment of microalbuminuria. Diabetes 39:245–249, 1990
40. POULSEN PL, EBBEHOJ E, HANSEN KW, MOGENSEN CE: High normo-
or low microalbuminuria: Basis for intervention in insulin-dependent
diabetes mellitus. Kidney Int 52(Suppl 63):S15–S18, 1997
41. HANSEN KW, MAU PEDERSEN M, MARSHALL SM, CHRISTIANSEN JS,
MOGENSEN CE: Circadian variation of blood pressure in patients with
diabetic nephropathy. Diabetologia 35:1074–1079, 1992
42. NIELSEN FS, ROSSING P, BANG LE, SVENDSEN TL, GAIL MA, SMIDT
UM: On the mechanisms of blunted nocturnal decline in arterial
blood pressure in NIDDM patients with diabetic nephropathy. Dia-
betes 44:783–789, 1995
43. NELSON RG, PETTITT DJ, BAIRD HR, CHARLES MA, LIU QZ, BEN-
NETT PH, KNOWLER WC: Prediabetic blood pressure predicts urinary
albumin secretion after the onset of type 2 (non-insulin-dependent)
diabetes mellitus in Pima Indians. Diabetologia 36:998–1001, 1993
44. CHRISTENSEN CK, MOGENSEN CE: Antihypertensive treatment: long-
term reversal of progression of albuminuria in incipient diabetic
nephropathy: A longitudinal study of renal function. J Diabetes Compl
1:45–52, 1987
45. GAMBARDELLA S, FRONTONI S, FELICI MG, SPALLONE V, GARGIULO
D, MORANO S, MENZINGER G: Efficacy of antihypertensive treatment
with indapamine in patients with non-insulin-dependent diabetes and
persistent microalbuminuria. Am J Cardiol 65:46H–50H, 1990
46. BIESENBACH G, JANKO O, ZAZGORNIK J: Similar rate of progression in
the predialysis phase in type I and type II diabetes mellitus. Nephrol
Dial Transplant 9:1097–1102, 1994
47. PERNEGER TV, BRANCATI FL, WHELTON PK, KLAG MJ: End-stage
renal disease attributable to diabetes mellitus. Ann Intern Med 121:
912–918, 1994
48. MATHIESEN ER, BORCH-JOHNSEN K, JENSEN DV, DECKERT T: Im-
proved survival in patients with diabetic nephropathy. Diabetologia
32:884–886, 1989
49. BJO¨RK S, NYBERG G, MULEC H, GRANERUS G, HERLITZ H, AURELL
M: Beneficial effect of angiotensin converting enzyme inhibition on
renal function in patients with diabetic nephropathy. Br Med J
293:471–474, 1986
50. PARVING HH, JACOBSEN PJ, ROSSING K, SMIDT UM, HOMMEL E,
ROSSING P: Beneficts of long-term antihypertensive treatment on
prognosis in diabetic nephropathy. Kidney Int 49:1778–1782, 1996
51. IWANO M, KUBO A, NISHINO T, SATO H, NISHIOKA H, AKAI Y,
KURIOKA H, FUJII Y, KANAUCHI M, SHIIKI H, DOHI K: Quantification
of glomerular TGF-b1 mRNA in patients with diabetes mellitus.
Kidney Int 49:1120–1126, 1996
52. LAFFEL LMB, MCGILL JB, GANS DJ: The beneficial effect of angio-
tensin converting enzyme inhibition with captopril on diabetic ne-
phropathy in normotensive IDDM patients with microalbuminuria.
Am J Med 99:497–504, 1995
53. MORELLI E, LOON N, MEYER T, PETERS W, MYERS BD: Effects of
converting-enzyme inhibition on barrier function in diabetic glomeru-
lopathy. Diabetes 39:76–82, 1990
54. TAGUMA Y, KITAMOTO Y, FUTAKI G: Effect of captopril on heavy
proteinuria in azotemic diabetics N Engl J Med 313:1617–1620, 1985
55. MATHIESEN ER, HOMMEL E, GIESE J, PARVING HH: Efficacy of
captopril in postponing nephropathy in normotensive insulin depen-
dent diabetic patients with microalbuminuria. Br Med J 303:81–87,
1991
56. RAVID M, LANG R, RACHMANI R, LISHNER M: Long term renopro-
tective effect of angiotensin converting enzyme inhibition in non
insulin dependent diabetes mellitus. Arch Intern Med 156:286–289,
1996
57. THE MICROALBUMINURIA CAPTOPRIL STUDY GROUP: Captopril re-
duces the risk of nephropathy in IDDM patients with microalbumin-
uria. Diabetologia 39:587–593, 1996
58. ANONYMOUS: Comparison between perindopril and nifedipine in
hypertensive and normotensive diabetic patients with microalbumin-
uria. Melbourne Diabetic Nephropathy Study Group. Br Med J
302:210–216, 1991
59. AGARDH CD, GARCIA-PUIG J, CHARBONELL B, ANGELKORT B, BAR-
NETT AH: Greater reduction of urinary albumin excretion in hyper-
tensive type II diabetic patients with incipient nephropathy by lisino-
pril than by nifedipine. J Hum Hypertens 10:185–192, 1996
60. JUNGMANN E, HAAK T, MALANYN M, MORTASAWI N, SCHERERICH J,
USADEL KH: Comparative study on renal effects of nitrendipine vs
enalapril in microalbuminuric patients with type I diabetes mellitus.
(abstract) Diabetologia 35:A149, 1992
61. RUGGENENTI P, MOSCONI L, BIANCHI L, CORTESI L, CAMPANA M,
PAGANI G, MECCA G, REMUZZI G: Long-term treatment with either
enalapril or nitrendipine stabilizes albuminuria and increases glomer-
ular filtration rate in non insulin dependent diabetic patients. Am J
Kidney Dis 24:753–761, 1994
62. GRIFFIN K, PICKEN M, BIDANI AK: Deleterious effects of calcium
channel blockade on pressure transmission and glomerular injury in
rats remnant kidneys. (abstract) J Clin Invest 96:793, 1995
63. PICKEN M, GRIFFIN K, BAKRIS GL, BIDANI AK: Comparative effects of
four different calcium antagonists on progression of renal disease in a
remnant kidney model. (abstract) J Am Soc Nephrol 7:1586, 1996
64. ANDERSON S, RENNKE HG, BRENNER BM: Nifedipine versus fosino-
pril in uninephrectomized diabetic rats. Kidney Int 41:891–897, 1992
65. BROWN S, WALTON C, CRAWFORD P, BAKRIS GL: Compqarative renal
hemodynamic effects of an ACE inhibitor or calcium antagonist on
progression of diabetic nephropathy in the dog. (abstract) Kidney Int
43:1210, 1993
66. RAIJ L, KEANE WF: Glomerular mesangium: Its function and rela-
tionship to angiotensin II. Am J Med 79:24–30, 1985
67. SHULTZ PJ, RAIJ L: Inhibition of human mesangial cell proliferation
by calcium channel blockers. Hypertension 15:I76–I80, 1989
68. SCHNACK C, CAPEK M, BANYAI M, KAUTZKY-WILLER A, PRAGER R,
SCHERNTHANER G: Long-term treatment with nifedipine reduces
urinary albumin excretion and glomerular filtration rate in normoten-
sive type I diabetic patients with microalbuminuria. Acta Diabetol
31:14–18, 1994
69. MOSCONI L, RUGGENENTI P, PERNA A, MECCA G, REMUZZI G:
Nitrendipine and enalapril improve albuminuria and glomerular
filtration rate in non-insulin dependent diabetes. Kidney Int 49(Suppl
55):S91–S93, 1996
70. BRETZEL RG, BOLLEN CC, MASER E, FEDERLIN KF: Nephroprotec-
tive effects of nitrendipine in hypertensive type I and type II diabetic
patients. Am J Kidney Dis 21(Suppl 3):S53–S64, 1993
71. PARVING HH, ROSSING P, HOMMEL E, SMIDT UM: Angiotensin
converting enzyme inhibition in diabetic nephropathy. Ten years
experience. Am J Kidney Dis 26:99–107, 1995
72. BAKRIS GL, COPLEY JB, VICKNAIR N, SADLER R, LEURGANS S:
Calcium channel blockers versus other antihypertensive therapies on
progression of NIDDM associated nephropathy. Kidney Int 50:1641–
1650, 1996
73. BAKRIS GL: Hypertension in diabetic patients. An overview of inter-
ventional studies to preserve renal function. Am J Hypertens 6:140S–
147S, 1993
74. SLATAPER R, VICKNAIR N, SADLER R, BAKRIS GL: Comparative
effects of different antihypertensive treatments on progression of
diabetic renal disease. Arch Intern Med 153:973–980, 1993
75. BO¨HLEN L, DE COURTEN M, WEIDMANN P: Comparative study of the
effect of ACE inhibitors and other antihypertensive agents on pro-
teinuria in diabetic patients. Am J Hypertens 7(Suppl):S84–S92, 1994
76. BRETZEL G: Effects of antihypertensive drugs on renal function in
patients with diabetic nephropathy. Am J Hypertens 10:S208–S217,
1997
77. WEIDMANN P, SCHNEIDER M, BO¨HLEN L: Therapeutic efficacy of
different antihypertensive drugs in human diabetic nephropathy: An
updated meta-analysis. Nephrol Dial Transplant 10(Suppl 9):39–45,
1995
Lun˜o et al: Antihypertensive therapy in diabetic nephropathyS-118
78. CARMINES PK, NAVAR LJ: Disparate effects of Ca channel blockade
on afferent and efferent arteriolar responses to ANG II. Am J Physiol
256:F1015–F1020, 1989
79. RAIJ L: Effects of ACE inhibitors and calcium channel blockers on the
development of glomerular sclerosis in models of renal damage.
Nephrol Dial Transplant 10(Suppl 9):23–27, 1995
80. BROWN S, WALTON C, CRAWFORD P, BAKRIS GL: Comparative renal
hemodynamic effects of an ACE- inhibitor or calcium antagonist on
progression of diabetic nephropathy in a dog. Kidney Int 43:1210–
1218, 1993
81. BAKRIS GL, BARNHILL BW, SADLER R: Treatment of arterial hyper-
tension in diabetic humans: Importance of therapeutic selection.
Kidney Int 41:912–919, 1992
82. FIORETTO P, FRIGATO F, VELUSSI M: Effects of angiotensin-convert-
ing enzyme inhibitors and calcium antagonists on atrial natriuretic
peptide release and action on albumin excretion rate in hypertensive
insulin-dependent diabetic patients. Am J Hypertens 5:837–846, 1992
83. BAKRIS GL, WEIR M, DE QUATTRO V, ROSENDORFF C, MCMAHON G:
Renal hemodynamic and antiproteinuric response to an ACE inhibi-
tor, trandolapril or calcium antagonist, verapamil alone or in fixed
dose combination in patients with diabetic nephropathy: A random-
ized multicenter study. (abstract) J Am Soc Nephrol 7(Suppl 9):A1479,
1996
84. BAKRIS GL, WILLIANS B: Angiotensin converting enzyme inhibitors
and calcium antagonists alone or combined: Does the progression of
renal disease differ? J Hypertens 13(Suppl):S95–S101, 1995
Lun˜o et al: Antihypertensive therapy in diabetic nephropathy S-119
